ERBB2 and breast carcinoma: Tan et al. 65 reported that a CPP conjugated with an anti-HER-2/neu peptide mimetic (AHNP), an ErbB2 extracellular domain-binding peptide, preferentially targeted ErbB2-overexpressing in breast cancer cells.